Ten23 Expands Sterile Manufacturing Capacity at VIVA 1 Facility

Image Credit: Adobe Stock Images/Stavros

ten23 health, a contract development and manufacturing organization (CDMO), announced a capacity expansion for the manufacture of sterile drug product at its Visp facility, according to a press release.

Due to customer demand for sterile fill and finish services, the expansion will head to VIVA 1, Visp Valais, Switzerland, at a sterile manufacturing facility. Following successful completion of the GMP inspection by Swissmedic and an obtained GMP license, the new storage areas are set to become operational in September 2023. Additionally, the output of ten23’s existing sterile manufacturing facility in Visp will be gradually increased by a further 50% capacity by hiring more staff to operate an additional shift.

According to the press release, further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing. Two additional filling lines for sterile commercial supplies of ready-to-use syringes, cartridges, and vials and liquid or freeze-dried clinical and commercial vial supplies will all be a part of VIVA 2. This project is signed for manufacturing in 2024 and 2025.

“We are thrilled to offer our customers additional sterile manufacturing capacity for sophisticated and highly precise Drug Product-presentations such as syringes and cartridges, increased capacity until the two new production lines becoming fully operational.” said Professor Hanns-Christian Mahler, PhD, CEO of ten23 health, in a press release. “With recent demand increases for clinical as well as commercial drug launches, our customers are keen to take advantage of increased capacity from the existing VIVA 1® facility, before the new plant VIVA 2® will be utilized for larger scales.”